# AET02 variant 1 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                     Placebo     Xanomeline High Dose   Xanomeline Low Dose   All Patients
        MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)            (N=254)   
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event     46 (53.5%)        64 (88.9%)            71 (74.0%)        181 (71.3%) 
      Overall total number of events                                   96               233                    228               557     
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                             
        Total number of patients with at least one adverse event   19 (22.1%)        34 (47.2%)            35 (36.5%)         88 (34.6%) 
        Total number of events                                         37                86                    90                213     
        PRURITUS                                                    8 (9.3%)         26 (36.1%)            23 (24.0%)         57 (22.4%) 
        ERYTHEMA                                                   9 (10.5%)         14 (19.4%)            15 (15.6%)         38 (15.0%) 
        RASH                                                        5 (5.8%)         11 (15.3%)            13 (13.5%)         29 (11.4%) 
        SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)              6 (6.2%)          14 (5.5%)  
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                               
        Total number of patients with at least one adverse event   15 (17.4%)        30 (41.7%)            35 (36.5%)         80 (31.5%) 
        Total number of events                                         29                84                    88                201     
        APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)            23 (24.0%)         50 (19.7%) 
        APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)            13 (13.5%)         30 (11.8%) 
        APPLICATION SITE DERMATITIS                                 5 (5.8%)          7 (9.7%)              9 (9.4%)          21 (8.3%)  
        APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)              9 (9.4%)          21 (8.3%)  
      NERVOUS SYSTEM DISORDERS                                                                                                           
        Total number of patients with at least one adverse event    8 (9.3%)         15 (20.8%)            10 (10.4%)         33 (13.0%) 
        Total number of events                                         11                26                    18                 55     
        DIZZINESS                                                   2 (2.3%)         11 (15.3%)             9 (9.4%)          22 (8.7%)  
        HEADACHE                                                    7 (8.1%)          6 (8.3%)              3 (3.1%)          16 (6.3%)  
      GASTROINTESTINAL DISORDERS                                                                                                         
        Total number of patients with at least one adverse event   12 (14.0%)        9 (12.5%)              9 (9.4%)          30 (11.8%) 
        Total number of events                                         13                16                    13                 42     
        DIARRHOEA                                                  9 (10.5%)          3 (4.2%)              6 (6.2%)          18 (7.1%)  
        NAUSEA                                                      3 (3.5%)          6 (8.3%)              3 (3.1%)          12 (4.7%)  
      CARDIAC DISORDERS                                                                                                                  
        Total number of patients with at least one adverse event    2 (2.3%)         8 (11.1%)              7 (7.3%)          17 (6.7%)  
        Total number of events                                         2                 12                    10                 24     
        SINUS BRADYCARDIA                                           2 (2.3%)         8 (11.1%)              7 (7.3%)          17 (6.7%)  
      INFECTIONS AND INFESTATIONS                                                                                                        
        Total number of patients with at least one adverse event    2 (2.3%)          6 (8.3%)              4 (4.2%)          12 (4.7%)  
        Total number of events                                         4                 8                      9                 21     
        NASOPHARYNGITIS                                             2 (2.3%)          6 (8.3%)              4 (4.2%)          12 (4.7%)  
      VASCULAR DISORDERS                                                                                                                 
        Total number of patients with at least one adverse event       0              1 (1.4%)                  0              1 (0.4%)  
        Total number of events                                         0                 1                      0                 1      
        WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0              1 (0.4%)  

# AET02 variant 2 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                     Placebo     Xanomeline High Dose   Xanomeline Low Dose   All Patients
        MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)            (N=254)   
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event     46 (53.5%)        64 (88.9%)            71 (74.0%)        181 (71.3%) 
      Overall total number of events                                   96               233                    228               557     
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                             
        Total number of patients with at least one adverse event   19 (22.1%)        34 (47.2%)            35 (36.5%)         88 (34.6%) 
        PRURITUS                                                    8 (9.3%)         26 (36.1%)            23 (24.0%)         57 (22.4%) 
        ERYTHEMA                                                   9 (10.5%)         14 (19.4%)            15 (15.6%)         38 (15.0%) 
        RASH                                                        5 (5.8%)         11 (15.3%)            13 (13.5%)         29 (11.4%) 
        SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)              6 (6.2%)          14 (5.5%)  
        Total number of events                                         37                86                    90                213     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                               
        Total number of patients with at least one adverse event   15 (17.4%)        30 (41.7%)            35 (36.5%)         80 (31.5%) 
        APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)            23 (24.0%)         50 (19.7%) 
        APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)            13 (13.5%)         30 (11.8%) 
        APPLICATION SITE DERMATITIS                                 5 (5.8%)          7 (9.7%)              9 (9.4%)          21 (8.3%)  
        APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)              9 (9.4%)          21 (8.3%)  
        Total number of events                                         29                84                    88                201     
      NERVOUS SYSTEM DISORDERS                                                                                                           
        Total number of patients with at least one adverse event    8 (9.3%)         15 (20.8%)            10 (10.4%)         33 (13.0%) 
        DIZZINESS                                                   2 (2.3%)         11 (15.3%)             9 (9.4%)          22 (8.7%)  
        HEADACHE                                                    7 (8.1%)          6 (8.3%)              3 (3.1%)          16 (6.3%)  
        Total number of events                                         11                26                    18                 55     
      GASTROINTESTINAL DISORDERS                                                                                                         
        Total number of patients with at least one adverse event   12 (14.0%)        9 (12.5%)              9 (9.4%)          30 (11.8%) 
        DIARRHOEA                                                  9 (10.5%)          3 (4.2%)              6 (6.2%)          18 (7.1%)  
        NAUSEA                                                      3 (3.5%)          6 (8.3%)              3 (3.1%)          12 (4.7%)  
        Total number of events                                         13                16                    13                 42     
      CARDIAC DISORDERS                                                                                                                  
        Total number of patients with at least one adverse event    2 (2.3%)         8 (11.1%)              7 (7.3%)          17 (6.7%)  
        SINUS BRADYCARDIA                                           2 (2.3%)         8 (11.1%)              7 (7.3%)          17 (6.7%)  
        Total number of events                                         2                 12                    10                 24     
      INFECTIONS AND INFESTATIONS                                                                                                        
        Total number of patients with at least one adverse event    2 (2.3%)          6 (8.3%)              4 (4.2%)          12 (4.7%)  
        NASOPHARYNGITIS                                             2 (2.3%)          6 (8.3%)              4 (4.2%)          12 (4.7%)  
        Total number of events                                         4                 8                      9                 21     
      VASCULAR DISORDERS                                                                                                                 
        Total number of patients with at least one adverse event       0              1 (1.4%)                  0              1 (0.4%)  
        WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0              1 (0.4%)  
        Total number of events                                         0                 1                      0                 1      

# AET02 variant 3 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                                                                             
        High Level Term                                               Placebo     Xanomeline High Dose   Xanomeline Low Dose
          MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)       
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event       46 (53.5%)        64 (88.9%)            71 (74.0%)     
      Overall total number of events                                     96               233                    228        
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                                
        Total number of patients with at least one adverse event     19 (22.1%)        34 (47.2%)            35 (36.5%)     
        Total number of events                                           37                86                    90         
        HLT_0778                                                                                                            
          Total number of patients with at least one adverse event    8 (9.3%)         26 (36.1%)            23 (24.0%)     
          Total number of events                                         11                38                    35         
          PRURITUS                                                    8 (9.3%)         26 (36.1%)            23 (24.0%)     
        HLT_0284                                                                                                            
          Total number of patients with at least one adverse event   9 (10.5%)         14 (19.4%)            15 (15.6%)     
          Total number of events                                         13                22                    24         
          ERYTHEMA                                                   9 (10.5%)         14 (19.4%)            15 (15.6%)     
        HLT_0762                                                                                                            
          Total number of patients with at least one adverse event    5 (5.8%)         11 (15.3%)            13 (13.5%)     
          Total number of events                                         9                 18                    18         
          RASH                                                        5 (5.8%)         11 (15.3%)            13 (13.5%)     
        HLT_0583                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)          5 (6.9%)              6 (6.2%)      
          Total number of events                                         4                 8                     13         
          SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)              6 (6.2%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                  
        Total number of patients with at least one adverse event     15 (17.4%)        30 (41.7%)            35 (36.5%)     
        Total number of events                                           29                84                    88         
        HLT_0317                                                                                                            
          Total number of patients with at least one adverse event    6 (7.0%)         21 (29.2%)            23 (24.0%)     
          Total number of events                                         10                34                    34         
          APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)            23 (24.0%)     
        HLT_0617                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)         14 (19.4%)            13 (13.5%)     
          Total number of events                                         3                 22                    21         
          APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)            13 (13.5%)     
        HLT_0061                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)         9 (12.5%)              9 (9.4%)      
          Total number of events                                         7                 16                    18         
          APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)              9 (9.4%)      
        HLT_0343                                                                                                            
          Total number of patients with at least one adverse event    5 (5.8%)          7 (9.7%)              9 (9.4%)      
          Total number of events                                         9                 12                    15         
          APPLICATION SITE DERMATITIS                                 5 (5.8%)          7 (9.7%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                              
        Total number of patients with at least one adverse event      8 (9.3%)         15 (20.8%)            10 (10.4%)     
        Total number of events                                           11                26                    18         
        HLT_0619                                                                                                            
          Total number of patients with at least one adverse event    2 (2.3%)         11 (15.3%)             9 (9.4%)      
          Total number of events                                         3                 17                    14         
          DIZZINESS                                                   2 (2.3%)         11 (15.3%)             9 (9.4%)      
        HLT_0064                                                                                                            
          Total number of patients with at least one adverse event    7 (8.1%)          6 (8.3%)              3 (3.1%)      
          Total number of events                                         8                 9                      4         
          HEADACHE                                                    7 (8.1%)          6 (8.3%)              3 (3.1%)      
      GASTROINTESTINAL DISORDERS                                                                                            
        Total number of patients with at least one adverse event     12 (14.0%)        9 (12.5%)              9 (9.4%)      
        Total number of events                                           13                16                    13         
        HLT_0148                                                                                                            
          Total number of patients with at least one adverse event   9 (10.5%)          3 (4.2%)              6 (6.2%)      
          Total number of events                                         10                3                      8         
          DIARRHOEA                                                  9 (10.5%)          3 (4.2%)              6 (6.2%)      
        HLT_0742                                                                                                            
          Total number of patients with at least one adverse event    3 (3.5%)          6 (8.3%)              3 (3.1%)      
          Total number of events                                         3                 13                     5         
          NAUSEA                                                      3 (3.5%)          6 (8.3%)              3 (3.1%)      
      CARDIAC DISORDERS                                                                                                     
        Total number of patients with at least one adverse event      2 (2.3%)         8 (11.1%)              7 (7.3%)      
        Total number of events                                           2                 12                    10         
        HLT_0644                                                                                                            
          Total number of patients with at least one adverse event    2 (2.3%)         8 (11.1%)              7 (7.3%)      
          Total number of events                                         2                 12                    10         
          SINUS BRADYCARDIA                                           2 (2.3%)         8 (11.1%)              7 (7.3%)      
      INFECTIONS AND INFESTATIONS                                                                                           
        Total number of patients with at least one adverse event      2 (2.3%)          6 (8.3%)              4 (4.2%)      
        Total number of events                                           4                 8                      9         
        HLT_0036                                                                                                            
          Total number of patients with at least one adverse event    2 (2.3%)          6 (8.3%)              4 (4.2%)      
          Total number of events                                         4                 8                      9         
          NASOPHARYNGITIS                                             2 (2.3%)          6 (8.3%)              4 (4.2%)      
      VASCULAR DISORDERS                                                                                                    
        Total number of patients with at least one adverse event         0              1 (1.4%)                  0         
        Total number of events                                           0                 1                      0         
        HLT_0154                                                                                                            
          Total number of patients with at least one adverse event       0              1 (1.4%)                  0         
          Total number of events                                         0                 1                      0         
          WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0         

# AET02 variant 4 is produced correctly

    Code
      res
    Output
                                                                  Placebo     Xanomeline High Dose   Xanomeline Low Dose
      MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)       
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event   46 (53.5%)        64 (88.9%)            71 (74.0%)     
      Total number of events                                         96               233                    228        
      PRURITUS                                                    8 (9.3%)         26 (36.1%)            23 (24.0%)     
      APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)            23 (24.0%)     
      ERYTHEMA                                                   9 (10.5%)         14 (19.4%)            15 (15.6%)     
      APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)            13 (13.5%)     
      RASH                                                        5 (5.8%)         11 (15.3%)            13 (13.5%)     
      DIZZINESS                                                   2 (2.3%)         11 (15.3%)             9 (9.4%)      
      APPLICATION SITE DERMATITIS                                 5 (5.8%)          7 (9.7%)              9 (9.4%)      
      APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)              9 (9.4%)      
      DIARRHOEA                                                  9 (10.5%)          3 (4.2%)              6 (6.2%)      
      SINUS BRADYCARDIA                                           2 (2.3%)         8 (11.1%)              7 (7.3%)      
      HEADACHE                                                    7 (8.1%)          6 (8.3%)              3 (3.1%)      
      SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)              6 (6.2%)      
      NASOPHARYNGITIS                                             2 (2.3%)          6 (8.3%)              4 (4.2%)      
      NAUSEA                                                      3 (3.5%)          6 (8.3%)              3 (3.1%)      
      WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0         

# AET02 variant 5 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                     Placebo     Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                        (N=86)            (N=72)                (N=96)       
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      Total number of patients with at least one adverse event     46 (53.5%)        64 (88.9%)                 0         
      Overall total number of events                                   96               233                     0         
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                              
        Total number of patients with at least one adverse event   19 (22.1%)        34 (47.2%)                 0         
        Total number of events                                         37                86                     0         
        PRURITUS                                                    8 (9.3%)         26 (36.1%)                 0         
        ERYTHEMA                                                   9 (10.5%)         14 (19.4%)                 0         
        RASH                                                        5 (5.8%)         11 (15.3%)                 0         
        SKIN IRRITATION                                             3 (3.5%)          5 (6.9%)                  0         
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                                
        Total number of patients with at least one adverse event   15 (17.4%)        30 (41.7%)                 0         
        Total number of events                                         29                84                     0         
        APPLICATION SITE PRURITUS                                   6 (7.0%)         21 (29.2%)                 0         
        APPLICATION SITE ERYTHEMA                                   3 (3.5%)         14 (19.4%)                 0         
        APPLICATION SITE DERMATITIS                                 5 (5.8%)          7 (9.7%)                  0         
        APPLICATION SITE IRRITATION                                 3 (3.5%)         9 (12.5%)                  0         
      NERVOUS SYSTEM DISORDERS                                                                                            
        Total number of patients with at least one adverse event    8 (9.3%)         15 (20.8%)                 0         
        Total number of events                                         11                26                     0         
        DIZZINESS                                                   2 (2.3%)         11 (15.3%)                 0         
        HEADACHE                                                    7 (8.1%)          6 (8.3%)                  0         
      GASTROINTESTINAL DISORDERS                                                                                          
        Total number of patients with at least one adverse event   12 (14.0%)        9 (12.5%)                  0         
        Total number of events                                         13                16                     0         
        DIARRHOEA                                                  9 (10.5%)          3 (4.2%)                  0         
        NAUSEA                                                      3 (3.5%)          6 (8.3%)                  0         
      CARDIAC DISORDERS                                                                                                   
        Total number of patients with at least one adverse event    2 (2.3%)         8 (11.1%)                  0         
        Total number of events                                         2                 12                     0         
        SINUS BRADYCARDIA                                           2 (2.3%)         8 (11.1%)                  0         
      INFECTIONS AND INFESTATIONS                                                                                         
        Total number of patients with at least one adverse event    2 (2.3%)          6 (8.3%)                  0         
        Total number of events                                         4                 8                      0         
        NASOPHARYNGITIS                                             2 (2.3%)          6 (8.3%)                  0         
      VASCULAR DISORDERS                                                                                                  
        Total number of patients with at least one adverse event       0              1 (1.4%)                  0         
        Total number of events                                         0                 1                      0         
        WOUND HAEMORRHAGE                                              0              1 (1.4%)                  0         

# AET02 variant 6 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
        SKIN IRRITATION                                      3 (3.5%)          5 (6.9%)              6 (6.2%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE DERMATITIS                          5 (5.8%)          7 (9.7%)              9 (9.4%)      
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        DIZZINESS                                            2 (2.3%)         11 (15.3%)             9 (9.4%)      
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        DIARRHOEA                                            9 (10.5%)         3 (4.2%)              6 (6.2%)      
        NAUSEA                                               3 (3.5%)          6 (8.3%)              3 (3.1%)      
      CARDIAC DISORDERS                                                                                            
        SINUS BRADYCARDIA                                    2 (2.3%)         8 (11.1%)              7 (7.3%)      
      INFECTIONS AND INFESTATIONS                                                                                  
        NASOPHARYNGITIS                                      2 (2.3%)          6 (8.3%)              4 (4.2%)      

# AET02 variant 7 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                                                                                    
        High Level Term                                       Placebo    Xanomeline High Dose   Xanomeline Low Dose
          MedDRA Preferred Term                               (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        HLT_0778                                                                                                   
          PRURITUS                                           8 (9.3%)         26 (36.1%)            23 (24.0%)     
        HLT_0284                                                                                                   
          ERYTHEMA                                           9 (10.5%)        14 (19.4%)            15 (15.6%)     
        HLT_0762                                                                                                   
          RASH                                               5 (5.8%)         11 (15.3%)            13 (13.5%)     
        HLT_0583                                                                                                   
          SKIN IRRITATION                                    3 (3.5%)          5 (6.9%)              6 (6.2%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        HLT_0317                                                                                                   
          APPLICATION SITE PRURITUS                          6 (7.0%)         21 (29.2%)            23 (24.0%)     
        HLT_0617                                                                                                   
          APPLICATION SITE ERYTHEMA                          3 (3.5%)         14 (19.4%)            13 (13.5%)     
        HLT_0061                                                                                                   
          APPLICATION SITE IRRITATION                        3 (3.5%)         9 (12.5%)              9 (9.4%)      
        HLT_0343                                                                                                   
          APPLICATION SITE DERMATITIS                        5 (5.8%)          7 (9.7%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        HLT_0619                                                                                                   
          DIZZINESS                                          2 (2.3%)         11 (15.3%)             9 (9.4%)      
        HLT_0064                                                                                                   
          HEADACHE                                           7 (8.1%)          6 (8.3%)              3 (3.1%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        HLT_0148                                                                                                   
          DIARRHOEA                                          9 (10.5%)         3 (4.2%)              6 (6.2%)      
        HLT_0742                                                                                                   
          NAUSEA                                             3 (3.5%)          6 (8.3%)              3 (3.1%)      
      CARDIAC DISORDERS                                                                                            
        HLT_0644                                                                                                   
          SINUS BRADYCARDIA                                  2 (2.3%)         8 (11.1%)              7 (7.3%)      
      INFECTIONS AND INFESTATIONS                                                                                  
        HLT_0036                                                                                                   
          NASOPHARYNGITIS                                    2 (2.3%)          6 (8.3%)              4 (4.2%)      

# AET02 variant 8 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        DIZZINESS                                            2 (2.3%)         11 (15.3%)             9 (9.4%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        DIARRHOEA                                            9 (10.5%)         3 (4.2%)              6 (6.2%)      
      CARDIAC DISORDERS                                                                                            
        SINUS BRADYCARDIA                                    2 (2.3%)         8 (11.1%)              7 (7.3%)      

# AET02 variant 9 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
        SKIN IRRITATION                                      3 (3.5%)          5 (6.9%)              6 (6.2%)      
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE DERMATITIS                          5 (5.8%)          7 (9.7%)              9 (9.4%)      
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        DIZZINESS                                            2 (2.3%)         11 (15.3%)             9 (9.4%)      
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        DIARRHOEA                                            9 (10.5%)         3 (4.2%)              6 (6.2%)      
        NAUSEA                                               3 (3.5%)          6 (8.3%)              3 (3.1%)      
      CARDIAC DISORDERS                                                                                            
        SINUS BRADYCARDIA                                    2 (2.3%)         8 (11.1%)              7 (7.3%)      
      INFECTIONS AND INFESTATIONS                                                                                  
        NASOPHARYNGITIS                                      2 (2.3%)          6 (8.3%)              4 (4.2%)      

# AET02 variant 10 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        DIZZINESS                                            2 (2.3%)         11 (15.3%)             9 (9.4%)      
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        DIARRHOEA                                            9 (10.5%)         3 (4.2%)              6 (6.2%)      
        NAUSEA                                               3 (3.5%)          6 (8.3%)              3 (3.1%)      
      CARDIAC DISORDERS                                                                                            
        SINUS BRADYCARDIA                                    2 (2.3%)         8 (11.1%)              7 (7.3%)      
      INFECTIONS AND INFESTATIONS                                                                                  
        NASOPHARYNGITIS                                      2 (2.3%)          6 (8.3%)              4 (4.2%)      

# AET02 variant 11 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE DERMATITIS                          5 (5.8%)          7 (9.7%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        DIARRHOEA                                            9 (10.5%)         3 (4.2%)              6 (6.2%)      

# AET02 variant 12 is produced correctly

    Code
      res
    Output
      MedDRA System Organ Class                               Placebo    Xanomeline High Dose   Xanomeline Low Dose
        MedDRA Preferred Term                                 (N=86)            (N=72)                (N=96)       
      —————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SKIN AND SUBCUTANEOUS TISSUE DISORDERS                                                                       
        PRURITUS                                             8 (9.3%)         26 (36.1%)            23 (24.0%)     
        ERYTHEMA                                             9 (10.5%)        14 (19.4%)            15 (15.6%)     
        RASH                                                 5 (5.8%)         11 (15.3%)            13 (13.5%)     
      GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS                                                         
        APPLICATION SITE PRURITUS                            6 (7.0%)         21 (29.2%)            23 (24.0%)     
        APPLICATION SITE ERYTHEMA                            3 (3.5%)         14 (19.4%)            13 (13.5%)     
        APPLICATION SITE IRRITATION                          3 (3.5%)         9 (12.5%)              9 (9.4%)      
      NERVOUS SYSTEM DISORDERS                                                                                     
        DIZZINESS                                            2 (2.3%)         11 (15.3%)             9 (9.4%)      
        HEADACHE                                             7 (8.1%)          6 (8.3%)              3 (3.1%)      
      GASTROINTESTINAL DISORDERS                                                                                   
        DIARRHOEA                                            9 (10.5%)         3 (4.2%)              6 (6.2%)      
      CARDIAC DISORDERS                                                                                            
        SINUS BRADYCARDIA                                    2 (2.3%)         8 (11.1%)              7 (7.3%)      
      INFECTIONS AND INFESTATIONS                                                                                  
        NASOPHARYNGITIS                                      2 (2.3%)          6 (8.3%)              4 (4.2%)      

